Innate Pharma SA (IPHA) stock
IPHANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as IPHYF
$1.03−0.30 (-22.56%)
Close on Nov 18, 2026Market cap $96.53MP/E –Yield –
Innate Pharma revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
For fiscal 2025 it was €9.01M, down 55.2% from the year before. The highest annual figure on record is €93.95M in fiscal 2018.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | €9.01M | -55.2% |
| FY2024 | Dec 31, 2024 | €20.12M | -67.4% |
| FY2023 | Dec 31, 2023 | €61.64M | +6.9% |
| FY2022 | Dec 31, 2022 | €57.67M | +133.5% |
| FY2021 | Dec 31, 2021 | €24.70M | -64.6% |
| FY2020 | Dec 31, 2020 | €69.77M | -18.3% |
| FY2019 | Dec 31, 2019 | €85.45M | -9.1% |
| FY2018 | Dec 31, 2018 | €93.95M | +113.4% |
| FY2017 | Dec 31, 2017 | €44.03M | – |
See a number that looks wrong?